AegirBio presentation and discussion session at ECTRIMS 2022
PRESSRELEASE September 6, 2022 AegirBio AB is pleased to announce that its abstract entitled “Quantitation of bivalent and monovalent natalizumab: providing a tool to study effects of IgG4 arm exchange.” has been accepted for poster presentation at the upcoming ECTRIMS 2022 congress to be held in Amsterdam on the 26-28 of October 2022.The ECTRIMS congress is the world’s largest gathering of neurologists and scientists focused on Multiple Sclerosis (MS). In addition to planned marketing outreach, including a booth in the exhibition hall, the company will be hosting a “Brain Exchange”